Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06215586
Registration number
NCT06215586
Ethics application status
Date submitted
13/12/2023
Date registered
22/01/2024
Date last updated
1/07/2025
Titles & IDs
Public title
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
Query!
Scientific title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Query!
Secondary ID [1]
0
0
2023-508737-13
Query!
Secondary ID [2]
0
0
CRD-750-202
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Cycle-2-PEF
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Heart Failure
0
0
Query!
Heart Failure Preserved Ejection Fraction
0
0
Query!
Cardiovascular Diseases
0
0
Query!
Heart Diseases
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tovinontrine (CRD-750
Treatment: Drugs - Placebo
Experimental: Tovinontrine (CRD-750) -
Placebo comparator: Placebo -
Treatment: Drugs: Tovinontrine (CRD-750
Tablets administered orally
Treatment: Drugs: Placebo
Tablets administered orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in biomarkers from Baseline to Week 12 - NT-proBNP
Query!
Assessment method [1]
0
0
The percent change in plasma NT-proBNP (Dose Cohort 3 versus placebo) will be calculated from Baseline to Week 12 using an ANCOVA model. If a statistically significant reduction in plasma NT-proBNP is detected (2-sided alpha=0.05), the next analysis will compare Dose 2 versus placebo at the (2-sided alpha = 0.05 level). If statistically significant, the next analysis will compare Dose 1 versus placebo.
Query!
Timepoint [1]
0
0
Baseline to Week 12
Query!
Secondary outcome [1]
0
0
Change in biomarkers at week 12 by treatment group - cGMP
Query!
Assessment method [1]
0
0
The percent change in urine and plasma cGMP from Baseline to Week 12 will be analyzed using ANCOVA and MMRM models by treatment group.
Query!
Timepoint [1]
0
0
Baseline to Week 12
Query!
Secondary outcome [2]
0
0
Change in biomarkers at week 12 by treatment group - BNP
Query!
Assessment method [2]
0
0
The percent change in BNP from Baseline to Week 12 will be analyzed using an ANCOVA model to evaluate individual dose comparisons.
Query!
Timepoint [2]
0
0
Baseline to Week 12
Query!
Secondary outcome [3]
0
0
Change in the biomarker ratio at Week 12 - NT-proBNP
Query!
Assessment method [3]
0
0
The change in the urine and plasma cGMP to NT-proBNP ratio at week 12 will be calculated for each treatment group
Query!
Timepoint [3]
0
0
Baseline to Week 12
Query!
Secondary outcome [4]
0
0
Change in the biomarker ratio at Week 12 - BNP
Query!
Assessment method [4]
0
0
The percent change in the urine and plasma cGMP to BNP ratio from Baseline to Week 12 will be calculated for each treatment group
Query!
Timepoint [4]
0
0
Baseline to Week 12
Query!
Secondary outcome [5]
0
0
Kansas City Cardiomyopathy Questionnaire-23-Clinical Summary Score
Query!
Assessment method [5]
0
0
Scaled 0 to 100 where lower scores represent worse health status than higher scores
Query!
Timepoint [5]
0
0
Baseline to Week 12
Query!
Secondary outcome [6]
0
0
New York Heart Association Classification
Query!
Assessment method [6]
0
0
Class I to IV are possible with a higher classification representing worsening heart failure status
Query!
Timepoint [6]
0
0
Baseline to Week 12
Query!
Secondary outcome [7]
0
0
Treatment Emergent Adverse Events (TEAEs)
Query!
Assessment method [7]
0
0
The number of participants with TEAEs including drug related AEs, serious AEs (SAEs), and AEs leading to study drug discontinuation will be assessed. The incidence of AEs will be presented by system organ class and preferred term according to the Medical Dictionary of Regulatory Activities.
Query!
Timepoint [7]
0
0
Baseline to Week 12
Query!
Secondary outcome [8]
0
0
Changes in laboratory assessments
Query!
Assessment method [8]
0
0
Number of participants with normal/ abnormal values at Baseline compared to normal/ abnormal values post-Baseline will be assessed for hematology, serum chemistry and urinalysis. Descriptive statistics of clinical laboratory assessment results and the change from Baseline will be presented by dose cohort and visit.
Query!
Timepoint [8]
0
0
Baseline to Week 12
Query!
Secondary outcome [9]
0
0
Changes in vital sign measurement: systolic and diastolic blood pressure
Query!
Assessment method [9]
0
0
Change from Baseline to Week 12 will be assessed for systolic and diastolic blood pressure (mmHg). Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.
Query!
Timepoint [9]
0
0
Baseline to Week 12
Query!
Secondary outcome [10]
0
0
Changes in vital sign measurement: pulse rate
Query!
Assessment method [10]
0
0
The change from Baseline to Week 12 will be assessed for pulse rate (bpm). Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.
Query!
Timepoint [10]
0
0
Baseline to Week 12
Query!
Secondary outcome [11]
0
0
Changes in vital sign measurement: respiratory rate
Query!
Assessment method [11]
0
0
The change from Baseline to Week 12 will be assessed for respiratory rate (breaths/min). Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.
Query!
Timepoint [11]
0
0
Baseline to Week 12
Query!
Secondary outcome [12]
0
0
Changes in vital sign measurement: body temperature
Query!
Assessment method [12]
0
0
The change from Baseline to Week 12 will be assessed for body temperature. Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.
Query!
Timepoint [12]
0
0
Baseline to Week 12
Query!
Secondary outcome [13]
0
0
Changes in physical examination
Query!
Assessment method [13]
0
0
General physical exams will be carried out to detect any abnormalities in the cardiovascular, respiratory, and other body systems. Non-pre-existing abnormal physical examinations will be summarized by dose cohort and visit.
Query!
Timepoint [13]
0
0
Baseline to Week 12
Query!
Secondary outcome [14]
0
0
Changes in 12-lead electrocardiogram (ECG) measurements
Query!
Assessment method [14]
0
0
Number of participants who have normal/abnormal 12-lead ECG measurements at Baseline will be compared to normal/abnormal 12-lead ECG measurement post Baseline. Descriptive statistics of 12-lead ECG data and the change from baseline will be presented by dose cohort and visit.
Query!
Timepoint [14]
0
0
Baseline to Week 12
Query!
Secondary outcome [15]
0
0
Assessment of pharmacokinetics (PK): PK effect on NT-proBNP
Query!
Assessment method [15]
0
0
The plasma concentrations will be evaluated in the PK Population. The plasma concentration of tovinontrine will be summarized by dose cohort and visit. The correlation of plasma concentration with percent change in plasma NT-proBNP will be evaluated using Pearson's correlation coefficient.
Query!
Timepoint [15]
0
0
Baseline to Week 12
Query!
Secondary outcome [16]
0
0
Assessment of pharmacokinetics (PK): PK effect on plasma cGMP
Query!
Assessment method [16]
0
0
The plasma concentrations will be evaluated in the PK Population. The plasma concentration of tovinontrine will be summarized by dose cohort and visit. The correlation of plasma concentration with percent change in plasma cGMP will be evaluated using Pearson's correlation coefficient.
Query!
Timepoint [16]
0
0
Baseline to Week 12
Query!
Eligibility
Key inclusion criteria
* Is an adult male or female patient = 18 years of age
* Has evidence in the medical history supporting a diagnosis of clinical HF syndrome, NYHA functional class II to III, with the duration of at least 6 months prior to the time of Screening. The HF syndrome is defined by documentation of 1 or more of the following:
* At least 1 of the typical symptoms due to HF such as dyspnea and/or fatigue limiting exercise capacity;
* At least 1 of the typical signs of HF such as peripheral edema, elevated jugular venous pressure, pulmonary crackles; or
* Hospitalization, emergency department visit, or outpatient visit for HF requiring intravenous (IV) or subcutaneous (SQ) diuresis within the past 12 months.
* Has ejection fraction (EF) >40% and left atrial enlargement by transthoracic echocardiogram (TTE) performed and interpreted locally at the time of Screening;
* Has NT-proBNP level = 300 pg/mL at the time of Screening. Patients with atrial fibrillation or flutter at the time of Screening are required to have an NT proBNP level of =500 pg/mL at the time of Screening;
* Is on stable optimized doses of guideline-directed HF therapy, per Investigator's clinical judgment, for a minimum of 4 weeks prior to the time of Screening and during the Screening Period, with no planned changes after randomization; Has had no addition of new guideline-directed HF therapy within the 3 months prior to the time of Screening or during the Screening Period;
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Has documented EF = 60% by TTE within 6 months of the time of Screening or during the Screening Period;
* Has evidence of recent HF exacerbation defined by hospitalization or requirement for IV or SQ diuretics within 60 days of the time of Screening or during the Screening Period;
* Has a requirement for routine, scheduled outpatient IV infusions for HF (ie, inotropes, vasodilators, or diuretics) or routinely scheduled ultrafiltration;
* Has elective interventions (eg, percutaneous coronary intervention, device implantations, percutaneous structural heart disease interventions, cardiac and non-cardiac surgery) planned to occur during involvement in this study;
* Has acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, or carotid angioplasty within 60 days of the time of Screening or during the Screening Period;
* Has had a prior or planned orthotopic heart transplantation;
* Has presence of or plan for mechanical circulatory support;
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/02/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/10/2025
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
303
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Cardurion Investigative Site - Chermside
Query!
Recruitment postcode(s) [1]
0
0
- Chermside
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Oklahoma
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Oregon
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
South Dakota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Vermont
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Brugge
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Sint-Niklaas
Query!
Country [18]
0
0
Bulgaria
Query!
State/province [18]
0
0
Burgas
Query!
Country [19]
0
0
Bulgaria
Query!
State/province [19]
0
0
Gabrovo
Query!
Country [20]
0
0
Bulgaria
Query!
State/province [20]
0
0
Plovdiv
Query!
Country [21]
0
0
Bulgaria
Query!
State/province [21]
0
0
Ruse
Query!
Country [22]
0
0
Bulgaria
Query!
State/province [22]
0
0
Sofia
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Stara Zagora
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Quebec
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Hradec Králové
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Praha
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Berlin
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Brandenburg
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Lower Saxony
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Dresden
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Magdeburg
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Balatonfüred
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Budapest
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Gyöngyös
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Hatvan
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Orosháza
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Milan
Query!
Country [39]
0
0
Netherlands
Query!
State/province [39]
0
0
Eindhoven
Query!
Country [40]
0
0
Netherlands
Query!
State/province [40]
0
0
Groningen
Query!
Country [41]
0
0
Netherlands
Query!
State/province [41]
0
0
Hardenberg
Query!
Country [42]
0
0
Netherlands
Query!
State/province [42]
0
0
Sneek
Query!
Country [43]
0
0
Netherlands
Query!
State/province [43]
0
0
Zutphen
Query!
Country [44]
0
0
New Zealand
Query!
State/province [44]
0
0
Dunedin
Query!
Country [45]
0
0
Poland
Query!
State/province [45]
0
0
Grodzisk Mazowiecki
Query!
Country [46]
0
0
Poland
Query!
State/province [46]
0
0
Lublin
Query!
Country [47]
0
0
Poland
Query!
State/province [47]
0
0
Sopot
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Torun
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Warszawa
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Wroclaw
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Lódz
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Córdoba
Query!
Country [53]
0
0
Spain
Query!
State/province [53]
0
0
Málaga
Query!
Country [54]
0
0
Spain
Query!
State/province [54]
0
0
Santiago De Compostela
Query!
Country [55]
0
0
Spain
Query!
State/province [55]
0
0
Sevilla
Query!
Country [56]
0
0
Spain
Query!
State/province [56]
0
0
Valencia
Query!
Country [57]
0
0
Taiwan
Query!
State/province [57]
0
0
Kaohsiung
Query!
Country [58]
0
0
Taiwan
Query!
State/province [58]
0
0
Taipei county
Query!
Country [59]
0
0
Taiwan
Query!
State/province [59]
0
0
Taipei
Query!
Country [60]
0
0
Taiwan
Query!
State/province [60]
0
0
Taoyuan
Query!
Country [61]
0
0
United Kingdom
Query!
State/province [61]
0
0
Bridgend
Query!
Country [62]
0
0
United Kingdom
Query!
State/province [62]
0
0
Chichester
Query!
Country [63]
0
0
United Kingdom
Query!
State/province [63]
0
0
Dundee
Query!
Country [64]
0
0
United Kingdom
Query!
State/province [64]
0
0
Glasgow
Query!
Country [65]
0
0
United Kingdom
Query!
State/province [65]
0
0
Harrow
Query!
Country [66]
0
0
United Kingdom
Query!
State/province [66]
0
0
Isleworth
Query!
Country [67]
0
0
United Kingdom
Query!
State/province [67]
0
0
London
Query!
Country [68]
0
0
United Kingdom
Query!
State/province [68]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Cardurion Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
Query!
Trial website
https://clinicaltrials.gov/study/NCT06215586
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Gail Berman
Query!
Address
0
0
Senior VP Head, Clinical Development Cardurion
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Gail Berman
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
617-863-8088
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06215586
Download to PDF